Phillip Bergen

Phillip Bergen is a Lecturer in the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University, affiliated with the Centre for Medicine Use and Safety. His research focuses on antimicrobial resistance, pharmacokinetics/pharmacodynamics (PK/PD), and innovative treatments for multidrug-resistant pathogens. He has led multiple projects funded by organizations like the Australian Society for Antimicrobials and the National Health and Medical Research Council (NHMRC). His work includes developing combination therapies (e.g., polymyxin-rifampicin, fosfomycin-Pseudomonas aeruginosa targeting) and exploring bacteriophage genomics via platforms like PhageGE.

Research collaborations span global institutions, addressing UN Sustainable Development Goals related to health and innovation. Notable contributions include studies on colistin resistance mechanisms, lipid nanoparticle-based antimicrobials, and antibiotic synergy. Bergen has advised on drug delivery and stewardship committees, emphasizing practical clinical applications. His 77+ publications and 6 major projects underscore his impact in combating antimicrobial resistance through both experimental and computational approaches.